A Phase II, Randomized, Multi-center, Placebo-controlled, Double-blind Study to Investigate the Safety of GS-248, and Efficacy on Raynaud's Phenomenon (RP) and Peripheral Vascular Blood Flow, in Subjects With Systemic Sclerosis (SSc)

The primary objective of this study is to determine the safety, and evaluate the efficacy of GS-248 versus placebo on Raynaud's Phenomenon (RP) in subjects with Systemic Sclerosis (SSc).

开始日期2020-12-29

申办/合作机构

Gesynta Pharma AB

[+1]

NCT04617509

/ Completed临床1期

An Open, One-sequence, Three-period Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Oral Single Dosing of Two Different Solid Formulations of GS-248

The study will collect information about pharmacokinetics (PK), safety and tolerability following a single dose of GS-248 in two different oral solid formulations in capsules to healthy subjects. It will also collect information about pharmacokinetics (PK), safety and tolerability following a single dose of one of the two formulations of GS-248 in fed condition.

开始日期2020-03-31

申办/合作机构

Gesynta Pharma AB

[+1]

NCT04036227

/ Completed临床1期

A Phase I, Placebo-controlled, Double-blind, First-in-human Study to Investigate Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GS-248 Solution in Healthy Subjects and Patients With Systemic Sclerosis (SSc)

This is a First in Human (FIH), double-blinded, parallel-group, randomised, placebo-controlled study designed to evaluate the safety, tolerability, PK and PD of single and multiple ascending oral doses of GS-248 in healthy subjects.

开始日期2019-07-03

申办/合作机构

Gesynta Pharma AB

[+1]

100 项与 Vipoglanstat 相关的临床结果

登录后查看更多信息

100 项与 Vipoglanstat 相关的转化医学

登录后查看更多信息

100 项与 Vipoglanstat 相关的专利（医药）

登录后查看更多信息

项与 Vipoglanstat 相关的文献（医药）

2025-02-01·Rheumatology (Oxford, England)

A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor vipoglanstat in systemic sclerosis-related Raynaud's

Article

作者: Pauling, John D ; Kowalski, Jan ; Krasowska, Dorota ; Denton, Christopher P ; Vonk, Madelon C ; Wojteczek, Anna ; Tornling, Göran ; Hall, Frances ; van Laar, Jacob M ; Bhat, Smita ; Anderson, Marina ; Murray, Andrea ; Edenius, Charlotte ; Olas, Jacek ; Herrick, Ariane L ; Olsson, Anna ; Korkosz, Mariusz ; Smith, Vanessa ; Del Galdo, Francesco

Abstract:

Objective:

Our objective was to test the hypothesis, in a double-blind, placebo-controlled study that vipoglanstat, an inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1), which decreases prostaglandin E2 (PGE2) and increases prostacyclin biosynthesis, improves RP.

Methods:

Patients with SSc and ≥7 RP attacks during the last screening week prior to a baseline visit were randomized to 4 weeks treatment with vipoglanstat 120 mg or placebo. A daily electronic diary captured RP attacks (duration and pain) and Raynaud’s Condition Score, with change in RP attacks/week as the primary end point. Cold challenge assessments were performed at baseline and end of treatment. Exploratory end points included patients’ and physicians’ global impression of change, Assessment of Scleroderma-associated Raynaud’s Phenomenon questionnaire, mPGES-1 activity, and urinary excretion of arachidonic acid metabolites.

Results:

Sixty-nine subjects received vipoglanstat (n = 33) or placebo (n = 36). The mean weekly number of RP attacks [baseline; vipoglanstat 14.4 (S.D. 6.7), placebo 18.2 (12.6)] decreased by 3.4 (95% CI –5.8; –1.0) and 4.2 (–6.5; –2.0) attacks per week (P = 0.628), respectively. All patient-reported outcomes improved, with no difference between the groups. The mean change in recovery of peripheral blood flow after the cold challenge did not differ between the study groups. Vipoglanstat fully inhibited mPGES-1, resulting in 57% reduction of PGE2 and 50% increase of prostacyclin metabolites in the urine. Vipoglanstat was safe and well tolerated.

Conclusion:

Although vipoglanstat was safe, and well tolerated in a dose achieving full inhibition of mPGES-1, it was ineffective in SSc-related RP. Further development and evaluation of vipoglanstat will therefore be in other diseases where mPGES-1 plays a pathogenetic role.

Trial registration:

ClinicalTrials.gov, https://www.clinicaltrials.gov, NCT0474420.

2021-12-01·Journal of translational medicine2区 · 医学

Inhibition of microsomal prostaglandin E synthase-1 ameliorates acute lung injury in mice

2区 · 医学

ArticleOA

作者: Doods, Henri ; Pekcec, Anton ; Wu, Dongmei ; Nasseri, Saeed ; Feng, Huiying ; Lee, Dongwon ; Gurusamy, Malarvizhi ; Rampa, Dileep Reddy

Abstract:

Background:

To examine the effects of BI 1029539 (GS-248), a novel selective human microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor, in experimental models of acute lung injury (ALI) and sepsis in transgenic mice constitutively expressing the mPGES1 (Ptges) humanized allele.

Methods:

Series 1: Lipopolysaccharide (LPS)-induced ALI. Mice were randomized to receive vehicle, BI 1029539, or celecoxib. Series 2: Cecal ligation and puncture-induced sepsis. Mice were randomized to receive vehicle or BI 1029539.

Results:

Series 1: BI 1029539 or celecoxib reduced LPS-induced lung injury, with reduction in neutrophil influx, protein content, TNF-ɑ, IL-1β and PGE2 levels in bronchoalveolar lavage (BAL), myeloperoxidase activity, expression of mPGES-1, cyclooxygenase (COX)-2 and intracellular adhesion molecule in lung tissue compared with vehicle-treated mice. Notably, prostacyclin (PGI2) BAL concentration was only lowered in celecoxib-treated mice. Series 2: BI 1029539 significantly reduced sepsis-induced BAL inflammatory cell recruitment, lung injury score and lung expression of mPGES-1 and inducible nitric oxide synthase. Treatment with BI 1029539 also significantly prolonged survival of mice with severe sepsis. Anti-inflammatory and anti-migratory effect of BI 1029539 was confirmed in peripheral blood leukocytes from healthy volunteers.

Conclusions:

BI 1029539 ameliorates leukocyte infiltration and lung injury resulting from both endotoxin-induced and sepsis-induced lung injury.

2019-12-01·FASEB journal : official publication of the Federation of American Societies for Experimental Biology2区 · 生物学

Inhibition of human microsomal PGE2 synthase‐1 reduces seizure‐induced increases of P‐glycoprotein expression and activity at the blood‐brain barrier

2区 · 生物学

Article

作者: Pekcec, Anton ; Hosoya, Ken‐Ichi ; Kryscio, Richard J. ; Akanuma, Shin‐Ichi ; Doods, Henri ; Hartz, Anika M. S. ; Bauer, Björn ; Soldner, Emma L. B.

The cause of antiseizure drug (ASD) resistance in epilepsy is poorly understood. Here, we focus on the transporter P‐glycoprotein (P‐gp) that is partly responsible for limited ASD brain uptake, which is thought to contribute to ASD resistance. We previously demonstrated that cyclooxygenase‐2 (COX‐2) and the prostaglandin E receptor, prostanoid E receptor subtype 1, are involved in seizure‐mediated P‐gp up‐regulation. Thus, we hypothesized that inhibiting microsomal prostaglandin E2 (PGE2) synthase‐1 (mPGES‐1), the enzyme generating PGE2, prevents blood‐brain barrier P‐gp up‐regulation after status epilepticus (SE). To test our hypothesis, we exposed isolated brain capillaries to glutamate ex vivo and used a combined in vivo‐ex vivo approach by isolating brain capillaries from humanized mPGES‐1 mice to study P‐gp levels. We demonstrate that glutamate signaling through the NMDA receptor, cytosolic phospholipase A2, COX‐2, and mPGES‐1 increases P‐gp protein expression and transport activity levels. We show that mPGES‐1 is expressed in human, rat, and mouse brain capillaries. We show that BI1029539, an mPGES‐1 inhibitor, prevented up‐regulation of P‐gp expression and transport activity in capillaries exposed to glutamate and in capillaries from humanized mPGES‐1 mice after SE. Our data provide key signaling steps underlying seizure‐induced P‐gp up‐regulation and suggest that mPGES‐1 inhibitors could potentially prevent P‐gp up‐regulation in epilepsy.—Soldner, E. L. B., Hartz, A. M. S., Akanuma, S.‐I., Pekcec, A., Doods, H., Kryscio, R. J., Hosoya, K.‐I., Bauer, B. Inhibition of human microsomal PGE2 synthase‐1 reduces seizure‐induced increases of P‐glycoprotein expression and activity at the blood‐brain barrier. FASEB J. 33, 13966‐13981 (2019). www.fasebj.org

项与 Vipoglanstat 相关的新闻（医药）

2025-05-06

·orexo.com

Orexo Q1 2025 Interim Report

Q1 2025 highlights › Total net revenues of SEK 146.2 m (139.3) › EBITDA of SEK 5.9 m (15.9) › Net earnings of SEK -15.9 m (-8.9) › US Commercial segment net revenues of SEK 133.0 m (129.3), in local currency USD 12.5 m (12.4) › Cash flow from operating activities of SEK 32.9 m (-18.9), cash and cash equivalents of SEK 119.1 m (198.0) › Earnings per share before and after dilution amounted to SEK -0.46 (-0.26) › Positive topline data showed from clinical study of OX640, a nasal powder-based epinephrine product, in participants with allergic rhinitis › Future rights to royalties for OX-MPI, a new treatment for endometriosis, converted to shares in Gesynta Pharma valued at SEK 19 m. Important events after the end of the period › Orexo in collaboration with Abera Bioscience announced positive in-vivo data for powder-based intranasal vaccine formulated with the AmorphOX® technology. CEO comments in brief: Stable commercial business in a volatile market I’m pleased to report a stable start to 2025 from financial and product development perspectives. Our financial results in the quarter are in line with our expectations, including a positive EBITDA and only a slight decline in our cash position, caused solely by a weakening of the USD in March. Cash flow from operations is positive and have improved since last year. This is pleasing given that the first quarter can often be a challenging period, characterised by inventory reductions at wholesalers and a recurring seasonal decline in market demand due to resetting of deductibles, and formulary changes. We’re continuing to work with our nasal device supplier. As we’re yet to have a firm delivery date for the device, we’re now looking to resubmit OX124 to the FDA in mid-2026. Interest in OX640 from potential partners has increased since we in January reported positive results from our second OX640 clinical study, where we showed strong potential for a differentiated product. Uppsala, Sweden, May 6 2025 Nikolaj Sørensen President and CEO For full CEO comments see attached PDF. Contact persons quarterly report Nikolaj Sørensen, President and CEO Fredrik Järrsten, EVP and CFO Lena Wange, IR & Communications Director Tel: +46 18 780 88 00, +1 855 982 7658 E-mail: ir@orexo.com Presentation On May 6, at 2 pm CEST analysts, investors and media are invited to attend a presentation, incl. a Q&A. To attend via teleconference where you can ask questions verbally: Use this link (1): Orexo Q1 Report 2025 When registered you will be provided phone numbers and a conference ID to access the conference. To attend via webcast: Use this link (2): Orexo Q1 Report 2025 Prior to the call, presentation material will be available on the website under Investors/Rapport archive. This information is information that Orexo AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-05-06 08:00 CEST. Attachments Orexo Interim Report Q1 2025 May 5

临床结果疫苗财报

2025-02-06

·orexo.com

Orexo Interim Report Q4 2024, incl. Full Year Report

Q4 2024 highlights › Total net revenues of SEK 160.3 m (166.0) › EBITDA of SEK 28.9 m (12.4) › Impairment of intangible assets Deprexis® of SEK 71.1 m (0) and Vorvida® of SEK 28.1 m (0) › Net earnings of SEK -116.2 m (-18.6), adjusted net earnings amounted to SEK -18.9 m (-18.6) › US Commercial segment net revenues of SEK 152.1 m (151.3), in local currency USD 14.1 m (14.2) › Cash flow from operating activities of SEK 6.2 m (-2.6), cash and cash equivalents of SEK 123.3 m (171.0) › Earnings per share before and after dilution amounted to SEK -3.37 (-0.54) › Orexo agreed with GAIA on terminating the partnership for Deprexis ›Friedrich von Bohlen und Halbach elected as new board member at an Extraordinary General Meeting ›Patent litigation against Sun Pharmaceutical Industries reagarding Zubsolv® in the US was resolved ›Collaboration entered with Abera Bioscience to develop nasal powder vaccines based on the drug delivery technology AmorphOX® ›Financial outlook for 2025 on page 16. Important events after the end of the period ›Positive topline data showed from clinical study of OX640, a nasal powder-based adrenaline product, in participants with allergic rhinitis ›Future rights to royalties for OX-MPI, a new treatment for endometriosis, converted to shares in Gesynta Pharma valued at SEK 19 m and recognized in Q4 2024. CEO Comments in Brief: Resolving issues, unlocking more flexibility We end 2024 with an intense fourth quarter. The settlement in the patent litigation for Zubsolv® was an important milestone which in combination with continued stable revenue from Zubsolv gives us confidence that Zubsolv US will be an important contributor to our financial stability and ability to finance investments in other growth drivers. With the settlement we can start the process to clean the table and set a strategy to drive the long-term growth and shareholder value. Operationally, we saw mixed developments during the quarter. The timeline for OX124, our overdose rescue medication, has been extended, primarily due to delivery delays of components from one of our subcontractors. For OX640, our promising nasal drug for the treatment of anaphylaxis, we completed the second clinical study in December, this time in patients with allergic rhinitis. I am pleased with the successful data from the study, which further underscores that we have an exciting asset in our pipeline. Thanks to the AmorphOX technology we once again managed to show excellent bioavailability and we are confident OX640 will be a product with clear competitive advantages. Uppsala, Sweden, February 6, 2025 Nikolaj Sørensen President and CEO To read full version of CEO Comments see PDF. Contact persons quarterly report: Nikolaj Sørensen, President and CEO Fredrik Järrsten, EVP and CFO Lena Wange, IR & Communications Director Tel: +46 18 780 88 00, +1 855 982 7658, E-mail: ir@orexo.com. Presentation On Feburary 6, at 2 pm CET analysts, investors and media are invited to attend a presentation, incl. a Q&A. To attend via teleconference where you can ask questions verbally: https://conference.financialhearings.com/teleconference/?id=5007431 When registered you will be provided phone numbers and a conference ID to access the conference. To attend via webcast: https://orexo.events.inderes.com/q4-report-2024 Prior to the call, presentation material will be available on the website under Investors/Rapport archive

疫苗财报

2025-01-29

·PRNewswire

Endometriosis Clinical Trial Pipeline Gains Momentum as 15+ Key Companies at the Forefront | DelveInsight

Approximately 10% of women of reproductive age worldwide are affected by endometriosis, equating to about 190 million individuals. This substantial patient population necessitates effective treatments, propelling market demand this increasing disease prevalence is driving the market for endometriosis. LAS VEGAS, Jan. 29, 2025 /PRNewswire/ -- DelveInsight's ' Endometriosis Pipeline Insight 202 5 ' report provides comprehensive global coverage of pipeline endometriosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the endometriosis pipeline domain. Key Takeaways from the Endometriosis Pipeline Report DelveInsight's endometriosis pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for endometriosis treatment. Key endometriosis companies such as Kissei Pharmaceutical, Mithra Pharmaceuticals, Gesynta Pharma, Jiangsu Hengrui Medicine Co., Ferring Pharmaceuticals, Hope Medicine (Nanjing) Co., Ltd, VaRi Bioscience, SWK Holdings, Ananda Developments, TiumBio, Ironwood Pharmaceuticals, Chugai Pharmaceutical, Viramal, Organon, Mitsubishi Tanabe Pharma, Antev, Foraviset, ValiRx, EpicentRx, Temple Therapeutics, Celmatix, BCI Pharma, Gynica, PrecisionLife, Flightpath Biosciences, and others are evaluating new endometriosis drugs to improve the treatment landscape. Promising endometriosis pipeline therapies such as Linzagolix, Estelle, Vipoglanstat, SHR7280, Quinagolide, HMI-115, VR103, Ovarest, MRX1, TU2670, IW-3300, AMY-109, VML 0501, OG-6219, Teverelix trifluoroacetate, Raviset, VAL301, Nibrozetone, TTX334e, IntraVagS302, IntraVagS301, FP-300, and others are under different phases of endometriosis clinical trials. In October 2024, Lisata Therapeutics, Inc. announced that it has entered into a sponsored research agreement with the University of Cincinnati to investigate Lisata's novel cyclic peptide product candidate, certepetide, in combination with bevacizumab (a VEGF inhibitor) in a preclinical animal model for the treatment of endometriosis. In October 2024, Hope Medicine Inc. announced positive results from an interim analysis of a global Phase II study, " A Randomized, Multicenter, Double-Blind, Placebo -Controlled Phase 2 Study to Evaluate the Safety and Efficacy of HMI-115 in Women with Moderate to Severe Endometriosis Associated Pain Over a 12-Week Treatment Period". HMI-115 is a monoclonal antibody that blocks the prolactin receptor. It is a first-in-class treatment for endometriosis. Notably, HMI-115 has been granted Breakthrough Therapy Designation by the National Medical Products Administration ("NMPA") in China. In May 2024, Neurocrine Biosciences, Inc. announced the initiation of its Phase I first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117567 in healthy adult participants. NBI-1117567 is an investigational, oral, M1/M4 (M1 preferring) selective muscarinic agonist for the potential treatment of neurological and neuropsychiatric conditions. In May 2024, TiumBio Co., Ltd. focused on discovering and developing innovative therapeutics for patients with rare and incurable diseases, announced positive topline results from its Phase 2a clinical trial of Merigolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in patients with moderate to severe endometriosis-associated pain. Request a sample and discover the recent advances in endometriosis treatment drugs @ Endometriosis Pipeline Report The endometriosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage endometriosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the endometriosis clinical trial landscape. Endometriosis Overview Endometriosis is a condition where tissue similar to the endometrium, which lines the uterus, grows outside of it. This often occurs in the lower abdomen or pelvic region but can occasionally be found elsewhere in the body. It commonly causes pelvic pain and may lead to infertility. The condition can begin with a person's first menstrual cycle and persist until menopause. The exact cause of endometriosis remains unknown, and there is currently no way to prevent it. While there is no cure, symptoms can be managed through medications or, in some cases, surgery. Not all individuals with endometriosis experience symptoms, but common ones include pelvic pain, painful periods, discomfort during sexual intercourse, and challenges with conception. Approximately 10% of women of reproductive age are affected, though the true prevalence is difficult to determine as diagnosis often requires laparoscopic surgery to confirm the presence of lesions. Endometriosis is a complex and widespread condition affecting women worldwide, regardless of ethnicity or social status. It is believed to result from multiple factors, including retrograde menstruation and cellular metaplasia, where cells outside the uterus transform into endometrial-like tissue. The condition is also heavily influenced by estrogen, which promotes inflammation, growth, and pain associated with the disease. Diagnosing endometriosis typically involves assessing a patient's menstrual and pelvic pain history. Although various diagnostic tools have been proposed, none are fully validated to identify individuals with certainty. Symptoms can mimic other conditions, leading to diagnostic delays. Imaging techniques like ultrasonography or MRI may be used to detect ovarian endometriomas, adhesions, or deep nodular lesions. Histologic confirmation, often following laparoscopic visualization, helps confirm the diagnosis but should not delay the initiation of empirical medical treatment. Treatment options range from conservative approaches, such as non-steroidal anti-inflammatory drugs (e.g., ibuprofen) to manage pain, to hormone-based medications that help control symptoms. Surgical intervention can both diagnose and treat endometriosis, with procedures to remove or destroy lesions and scar tissue, potentially alleviating pain and restoring normal pelvic anatomy. Find out more about endometriosis treatment drugs @ Drugs for Endometriosis Treatment A snapshot of the Endometriosis Pipeline Drugs mentioned in the report: Learn more about the emerging endometriosis pipeline therapies @ Endometriosis Clinical Trials Endometriosis Therapeutics Assessment The endometriosis pipeline report proffers an integral view of the endometriosis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Endometriosis Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical Therapeutics Assessment By Molecule Type: Monoclonal antibody, Peptides, Polymer, Small molecule, Gene therapy Therapeutics Assessment By Mechanism of Action: LHRH receptor antagonists, Estrogen receptor agonists, Hormone replacements, Mineralocorticoid receptor antagonists, Progesterone receptor agonists, Testosterone congener inhibitors, Prostaglandin-E synthase inhibitors, Gonadotropin-releasing hormone inhibitors, Dopamine D2 receptor agonists, Prolactin receptor antagonists, Key Endometriosis Companies: Kissei Pharmaceutical, Mithra Pharmaceuticals, Gesynta Pharma, Jiangsu Hengrui Medicine Co., Ferring Pharmaceuticals, Hope Medicine (Nanjing) Co., Ltd, VaRi Bioscience, SWK Holdings, Ananda Developments, TiumBio, Ironwood Pharmaceuticals, Chugai Pharmaceutical, Viramal, Organon, Mitsubishi Tanabe Pharma, Antev, Foraviset, ValiRx, EpicentRx, Temple Therapeutics, Celmatix, BCI Pharma, Gynica, PrecisionLife, Flightpath Biosciences, and others. Key Endometriosis Pipeline Therapies: Linzagolix, Estelle, Vipoglanstat, SHR7280, Quinagolide, HMI-115, VR103, Ovarest, MRX1, TU2670, IW-3300, AMY-109, VML 0501, OG-6219, Teverelix trifluoroacetate, Raviset, VAL301, Nibrozetone, TTX334e, IntraVagS302, IntraVagS301, FP-300 and others. Dive deep into rich insights for new drugs for endometriosis treatment, visit @ Endometriosis Drugs Table of Contents For further information on the endometriosis pipeline therapeutics, reach out @ Endometriosis Treatment Drugs Related Reports Endometriosis Market Endometriosis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key endometriosis companies including AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, SWK, Enteris BioPharma, Bayer, Hope Medicine, Tiumbio, Organon, among others. Endometriosis Epidemiology Forecast Endometriosis Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted endometriosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Endometriosis Pain Market Endometriosis Pain Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometriosis pain companies, including Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, among others. Endometriosis Pain Pipeline Endometriosis Pain Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis pain companies, including Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床2期临床结果突破性疗法临床1期

100 项与 Vipoglanstat 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
微血管疾病	临床2期	美国	Orexo US, Inc.	2022-01-30
微血管疾病	临床2期	美国	Gesynta Pharma AB	2022-01-30
雷诺病	临床2期	比利时	Gesynta Pharma AB	2020-12-29
雷诺病	临床2期	荷兰	Gesynta Pharma AB	2020-12-29
雷诺病	临床2期	波兰	Gesynta Pharma AB	2020-12-29
雷诺病	临床2期	英国	Gesynta Pharma AB	2020-12-29
视网膜色素变性	临床2期	比利时	Gesynta Pharma AB	2020-12-29
视网膜色素变性	临床2期	荷兰	Gesynta Pharma AB	2020-12-29
视网膜色素变性	临床2期	波兰	Gesynta Pharma AB	2020-12-29
视网膜色素变性	临床2期	英国	Gesynta Pharma AB	2020-12-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04744207 (CTgov)	临床2期	雷诺病 \| 系统性硬皮病 \| 视网膜色素变性	94	GS-248 (GS-248)	鬱餘衊遞齋顧醖願觸夢(遞製網憲願壓齋衊餘糧) = 衊夢壓壓獵築鬱鹹壓選憲淵製繭淵築構築壓鹽 (膚遞選鏇醖顧繭壓鬱簾, 膚壓鏇膚獵鑰夢構糧壓 ~ 構壓蓋鑰衊醖製願膚襯) 更多	-	2024-08-09
				Placebo (Placebo)	鬱餘衊遞齋顧醖願觸夢(遞製網憲願壓齋衊餘糧) = 遞遞選窪壓觸構繭顧廠憲淵製繭淵築構築壓鹽 (膚遞選鏇醖顧繭壓鬱簾, 淵鑰廠網鏇醖艱製顧壓 ~ 齋衊願壓築壓網遞鑰構) 更多
NCT04617509 (CTgov)	临床1期	-	14	GS-248 (Part I GS-248 Formulation A)	顧構繭壓艱築範夢製獵(鏇蓋蓋襯膚衊鏇膚簾窪) = 壓壓窪夢艱繭遞鹽淵範窪製簾顧鑰醖窪願鬱鏇 (糧繭網淵餘膚廠構糧蓋, 220.9) 更多	-	2021-08-31
				Formulation B GS-248 (Part I GS-248 Formulation B)	顧構繭壓艱築範夢製獵(鏇蓋蓋襯膚衊鏇膚簾窪) = 顧壓鏇壓遞築膚鹽鑰遞窪製簾顧鑰醖窪願鬱鏇 (糧繭網淵餘膚廠構糧蓋, 219.1) 更多